Nature:在体筛选800多个基因发现阻止癌症转移的新靶点

2017-01-15 生物谷 生物谷

来自英国桑格研究院的一项新研究为遏制肿瘤转移找到了新的药物靶点。相关研究结果发表在国际学术期刊Nature上。这项研究共发现23个参与癌细胞转移调控的基因,研究人员证明靶向其中一个基因——Spns2能够显著抑制肿瘤扩散。肿瘤转移是导致癌症病人死亡的首要原因。高达90%的癌症死亡都因癌症转移而发生,但是目前对癌症转移的调控机制仍了解不足。为了

来自英国桑格研究院的一项新研究为遏制肿瘤转移找到了新的药物靶点。相关研究结果发表在国际学术期刊Nature上。这项研究共发现23个参与癌细胞转移调控的基因,研究人员证明靶向其中一个基因——Spns2能够显著抑制肿瘤扩散。

肿瘤转移是导致癌症病人死亡的首要原因。高达90%的癌症死亡都因癌症转移而发生,但是目前对癌症转移的调控机制仍了解不足。

为了找出影响癌细胞转移的基因,研究人员借助敲除了单个基因的多种基因工程小鼠对肿瘤转移过程进行了研究。他们筛选了810个基因在其中发现了23个促进或抑制皮肤肿瘤细胞向肺部扩散的基因。其中的许多基因还会引起免疫系统的变化。

移除Spns2基因会引起最显著的变化,可以大大抑制肿瘤向肺部的扩散。随后研究人员又检测了该基因对其他癌症扩散的作用,包括结肠癌,肺癌和乳腺癌,并发现敲除Spns2也会抑制这几种癌症的转移。

来自桑格研究院的Dr. David Adams这样说道:“Spns2基因的缺失会导致肿瘤转移灶的形成受到显著抑制,因此该基因代表了一个新的药物靶点。我们发现缺失Spns2基因的小鼠其免疫细胞的比例也不同于正常小鼠,似乎该基因的缺失会促进免疫系统清除癌细胞。靶向该基因的药物或许可以帮助抑制或阻止癌细胞向身体其他部位的扩散。”

在该研究之前,有研究发现Spns2基因能够影响免疫系统,但是并未将其与肿瘤扩散联系在一起。该基因编码的蛋白能够对S1P这种脂质进行转运,S1P可以向免疫系统传递信号,在缺少转运蛋白后该信号不能正常运作从而导致机体内不同免疫细胞的比例发生变化。

该研究为抑制甚至阻止癌细胞转移提供了一个新的药物靶点,未来有望借助该方法达到治疗癌症的目的。

原始出处:

DOI: 10.1038/nature20792 

Genome-wide in vivo screen identifies novel host regulators of metastatic colonization

Louise van der Weyden, Mark J. Arends, Andrew D. Campbell, Tobias Bald, Hannah Wardle-Jones, Nicola Griggs, Martin Del Castillo Velasco-Herrera, Thomas Tüting, Owen J. Sansom, Natasha A. Karp, Simon Clare, Diane Gleeson, Edward Ryder, Antonella Galli, Elizabeth Tuck, Emma L. Cambridge, Thierry Voet, Iain C. Macaulay, Kim Wong, Sanger Mouse Genetics Project, Sarah Spiegel, Anneliese O. Speak & David J. Adams

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1881622, encodeId=293d188162219, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jul 13 19:17:00 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175127, encodeId=f7631e5127fa, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Thu Feb 09 11:49:54 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174279, encodeId=471f1e42792e, content=相关成果可以选择发表《CancerCellResearch》和《Chronic?DiseasesPreventionReview》期刊征稿,需要发表文章的可以投稿到邮箱editor@cancercellresearch.org, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5f42016340, createdName=1e20082fm27(暂无匿称), createdTime=Sun Feb 05 07:15:08 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174216, encodeId=e4cc1e421694, content=科技的进步,人类的发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6501973775, createdName=流恋离殇, createdTime=Sat Feb 04 21:22:36 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174135, encodeId=f12f1e4135f3, content=收藏,学习,进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Sat Feb 04 10:16:46 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174132, encodeId=bc6b1e41320d, content=收藏起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Sat Feb 04 10:07:33 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288194, encodeId=06c012881942c, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379094, encodeId=0e2b13e909460, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584364, encodeId=3c26158436480, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=)]
    2017-07-13 爆笑小医
  2. [GetPortalCommentsPageByObjectIdResponse(id=1881622, encodeId=293d188162219, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jul 13 19:17:00 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175127, encodeId=f7631e5127fa, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Thu Feb 09 11:49:54 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174279, encodeId=471f1e42792e, content=相关成果可以选择发表《CancerCellResearch》和《Chronic?DiseasesPreventionReview》期刊征稿,需要发表文章的可以投稿到邮箱editor@cancercellresearch.org, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5f42016340, createdName=1e20082fm27(暂无匿称), createdTime=Sun Feb 05 07:15:08 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174216, encodeId=e4cc1e421694, content=科技的进步,人类的发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6501973775, createdName=流恋离殇, createdTime=Sat Feb 04 21:22:36 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174135, encodeId=f12f1e4135f3, content=收藏,学习,进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Sat Feb 04 10:16:46 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174132, encodeId=bc6b1e41320d, content=收藏起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Sat Feb 04 10:07:33 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288194, encodeId=06c012881942c, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379094, encodeId=0e2b13e909460, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584364, encodeId=3c26158436480, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=)]
    2017-02-09 1771ae4158m

    学习一下很不错

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1881622, encodeId=293d188162219, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jul 13 19:17:00 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175127, encodeId=f7631e5127fa, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Thu Feb 09 11:49:54 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174279, encodeId=471f1e42792e, content=相关成果可以选择发表《CancerCellResearch》和《Chronic?DiseasesPreventionReview》期刊征稿,需要发表文章的可以投稿到邮箱editor@cancercellresearch.org, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5f42016340, createdName=1e20082fm27(暂无匿称), createdTime=Sun Feb 05 07:15:08 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174216, encodeId=e4cc1e421694, content=科技的进步,人类的发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6501973775, createdName=流恋离殇, createdTime=Sat Feb 04 21:22:36 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174135, encodeId=f12f1e4135f3, content=收藏,学习,进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Sat Feb 04 10:16:46 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174132, encodeId=bc6b1e41320d, content=收藏起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Sat Feb 04 10:07:33 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288194, encodeId=06c012881942c, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379094, encodeId=0e2b13e909460, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584364, encodeId=3c26158436480, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=)]
    2017-02-05 1e20082fm27(暂无匿称)

    相关成果可以选择发表《CancerCellResearch》和《Chronic?DiseasesPreventionReview》期刊征稿,需要发表文章的可以投稿到邮箱editor@cancercellresearch.org

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1881622, encodeId=293d188162219, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jul 13 19:17:00 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175127, encodeId=f7631e5127fa, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Thu Feb 09 11:49:54 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174279, encodeId=471f1e42792e, content=相关成果可以选择发表《CancerCellResearch》和《Chronic?DiseasesPreventionReview》期刊征稿,需要发表文章的可以投稿到邮箱editor@cancercellresearch.org, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5f42016340, createdName=1e20082fm27(暂无匿称), createdTime=Sun Feb 05 07:15:08 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174216, encodeId=e4cc1e421694, content=科技的进步,人类的发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6501973775, createdName=流恋离殇, createdTime=Sat Feb 04 21:22:36 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174135, encodeId=f12f1e4135f3, content=收藏,学习,进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Sat Feb 04 10:16:46 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174132, encodeId=bc6b1e41320d, content=收藏起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Sat Feb 04 10:07:33 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288194, encodeId=06c012881942c, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379094, encodeId=0e2b13e909460, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584364, encodeId=3c26158436480, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=)]
    2017-02-04 流恋离殇

    科技的进步,人类的发展

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1881622, encodeId=293d188162219, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jul 13 19:17:00 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175127, encodeId=f7631e5127fa, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Thu Feb 09 11:49:54 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174279, encodeId=471f1e42792e, content=相关成果可以选择发表《CancerCellResearch》和《Chronic?DiseasesPreventionReview》期刊征稿,需要发表文章的可以投稿到邮箱editor@cancercellresearch.org, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5f42016340, createdName=1e20082fm27(暂无匿称), createdTime=Sun Feb 05 07:15:08 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174216, encodeId=e4cc1e421694, content=科技的进步,人类的发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6501973775, createdName=流恋离殇, createdTime=Sat Feb 04 21:22:36 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174135, encodeId=f12f1e4135f3, content=收藏,学习,进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Sat Feb 04 10:16:46 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174132, encodeId=bc6b1e41320d, content=收藏起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Sat Feb 04 10:07:33 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288194, encodeId=06c012881942c, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379094, encodeId=0e2b13e909460, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584364, encodeId=3c26158436480, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=)]
    2017-02-04 wmu姿

    收藏,学习,进步

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1881622, encodeId=293d188162219, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jul 13 19:17:00 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175127, encodeId=f7631e5127fa, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Thu Feb 09 11:49:54 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174279, encodeId=471f1e42792e, content=相关成果可以选择发表《CancerCellResearch》和《Chronic?DiseasesPreventionReview》期刊征稿,需要发表文章的可以投稿到邮箱editor@cancercellresearch.org, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5f42016340, createdName=1e20082fm27(暂无匿称), createdTime=Sun Feb 05 07:15:08 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174216, encodeId=e4cc1e421694, content=科技的进步,人类的发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6501973775, createdName=流恋离殇, createdTime=Sat Feb 04 21:22:36 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174135, encodeId=f12f1e4135f3, content=收藏,学习,进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Sat Feb 04 10:16:46 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174132, encodeId=bc6b1e41320d, content=收藏起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Sat Feb 04 10:07:33 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288194, encodeId=06c012881942c, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379094, encodeId=0e2b13e909460, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584364, encodeId=3c26158436480, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=)]
    2017-02-04 wmu姿

    收藏起来

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1881622, encodeId=293d188162219, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jul 13 19:17:00 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175127, encodeId=f7631e5127fa, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Thu Feb 09 11:49:54 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174279, encodeId=471f1e42792e, content=相关成果可以选择发表《CancerCellResearch》和《Chronic?DiseasesPreventionReview》期刊征稿,需要发表文章的可以投稿到邮箱editor@cancercellresearch.org, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5f42016340, createdName=1e20082fm27(暂无匿称), createdTime=Sun Feb 05 07:15:08 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174216, encodeId=e4cc1e421694, content=科技的进步,人类的发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6501973775, createdName=流恋离殇, createdTime=Sat Feb 04 21:22:36 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174135, encodeId=f12f1e4135f3, content=收藏,学习,进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Sat Feb 04 10:16:46 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174132, encodeId=bc6b1e41320d, content=收藏起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Sat Feb 04 10:07:33 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288194, encodeId=06c012881942c, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379094, encodeId=0e2b13e909460, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584364, encodeId=3c26158436480, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=)]
    2017-01-17 lsndxfj
  8. [GetPortalCommentsPageByObjectIdResponse(id=1881622, encodeId=293d188162219, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jul 13 19:17:00 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175127, encodeId=f7631e5127fa, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Thu Feb 09 11:49:54 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174279, encodeId=471f1e42792e, content=相关成果可以选择发表《CancerCellResearch》和《Chronic?DiseasesPreventionReview》期刊征稿,需要发表文章的可以投稿到邮箱editor@cancercellresearch.org, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5f42016340, createdName=1e20082fm27(暂无匿称), createdTime=Sun Feb 05 07:15:08 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174216, encodeId=e4cc1e421694, content=科技的进步,人类的发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6501973775, createdName=流恋离殇, createdTime=Sat Feb 04 21:22:36 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174135, encodeId=f12f1e4135f3, content=收藏,学习,进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Sat Feb 04 10:16:46 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174132, encodeId=bc6b1e41320d, content=收藏起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Sat Feb 04 10:07:33 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288194, encodeId=06c012881942c, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379094, encodeId=0e2b13e909460, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584364, encodeId=3c26158436480, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1881622, encodeId=293d188162219, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jul 13 19:17:00 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175127, encodeId=f7631e5127fa, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Thu Feb 09 11:49:54 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174279, encodeId=471f1e42792e, content=相关成果可以选择发表《CancerCellResearch》和《Chronic?DiseasesPreventionReview》期刊征稿,需要发表文章的可以投稿到邮箱editor@cancercellresearch.org, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5f42016340, createdName=1e20082fm27(暂无匿称), createdTime=Sun Feb 05 07:15:08 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174216, encodeId=e4cc1e421694, content=科技的进步,人类的发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6501973775, createdName=流恋离殇, createdTime=Sat Feb 04 21:22:36 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174135, encodeId=f12f1e4135f3, content=收藏,学习,进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Sat Feb 04 10:16:46 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174132, encodeId=bc6b1e41320d, content=收藏起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Sat Feb 04 10:07:33 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288194, encodeId=06c012881942c, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379094, encodeId=0e2b13e909460, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584364, encodeId=3c26158436480, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Tue Jan 17 06:17:00 CST 2017, time=2017-01-17, status=1, ipAttribution=)]

相关资讯

综述:癌症免疫治疗的新机遇——CD73抗体

日前,Cell旗下《Trends in Cancer》发表了一篇题为“Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities”的综述。这一综述讨论了CD73与肿瘤发生、发展以及扩散之间的关系,强调了这一分子作为药物靶标的潜在价值,并表示CD73有望成为个性化癌症治疗中的新生物标志物。近年来,癌症免疫治疗的飞速发展使科学界对肿瘤生

抗癌史上的华人传奇李敏求医生,一段不应被忘却的故事

很少有人知道李敏求医生的名字。但知道他的人,都会为他做出的成就感到赞叹不已:李敏求医生是历史上首位用化疗治愈恶性实体肿瘤的科学家,也是首名荣获拉斯克临床医学奖的华人。他的故事,在人类抗击癌症的历史上留下了传奇一笔。“局外人中的局外人”李敏求医生在1919年出生于沈阳。1947年,他前往加州学习细菌学和免疫学,并在美国扎下了根。在芝加哥与纽约的几所医院经历辗转后,他最终来到了美国国立癌症研究所,

JAMA:看美国!35年癌症死亡率的差异趋势变化

癌症是美国发病率和死亡率的主要原因,并且也是导致经济负担增高的主要原因之一。近期,一项发表在JAMA杂志上的文章估计了美国各州的29种癌症的年龄标准化死亡率。研究数据来自国家卫生统计中心(NCHS)识别的死亡记录和人口普查局,NCHS和人类死亡率数据库的人口计数从1980年直至2014年。使用验证的小面积估计模型来估计29种癌症的死亡率:唇和口腔、鼻咽其他咽部、食管、胃、结肠和直肠、肝、胆囊和胆汁

Nat Cell Biol:控制休眠癌细胞,可能成为肿瘤治疗关键

科学家们通过控制原发肿瘤细胞周围环境,首次发现了迁移癌细胞在扩散后进入休眠状态并逃避化疗。这篇在纽约西奈山医学院领导下完成的研究论文发表在《自然细胞生物学》杂志上。研究人员认为,这项研究工作可能会导致能够改变大部分转移性癌症目前尚未治愈的现状,开发出全新的治疗药物和方法。大多数癌症死亡的原因是癌症转移——这个疾病阶段开始于癌细胞从原发肿瘤逃逸,通过血液或淋巴系统发生迁移,并在身体其他部位发生继

Nat Commun:肿瘤抑制蛋白反而促进癌症生长

来自杜兰大学的研究人员发现一种此前被认为是肿瘤抑制因子的蛋白PHLDB3事实上可以促进胰腺癌、前列腺癌、直肠癌、乳腺癌、肺癌及一些其他常见癌细胞的生长。这项新发现可能揭示了肿瘤克服关键肿瘤抑制因子p53的机制,这项新发现最近发表在《Nature Communications》上,将有助于开发出靶向一系列肿瘤的诊断和治疗方法。“现在我们已经发现了这种分子的促癌作用,因此我们可以把它作为抗癌靶标。”来

癌症16种超早期信号是什么?有助于早发现癌症

及早发现癌症症状是提高癌症患者生存几率的关键。美国“十佳家庭疗法”网站近日载文,根据美国“癌症网站”和《临床胃肠病学和肝病学杂志》等相关资料,总结出最容易被忽视的癌症症状。 1.不明原因消瘦。短时间内体重急剧下降往往是癌症第一信号。骤然消瘦在乳腺癌和肺癌患者中最常见,其他还包括肝癌和肠癌等。如果不运动不减肥,体重却莫名下降10%,应及时就医。 2.频繁发烧或感染。体内感染会导致发烧